Why Skills-First Leadership Is Replacing the Ivy League Playbook in the C-Suite
05/23/2025
No Comments
The old prestige pyramid—where Ivy League degrees and blue-chip consulting backgrounds paved the way to the CEO seat—is cracking.
April 24, 2023: According to The Wall Street Journal, Johnson & Johnson’s consumer health business is worth $40 billion ahead of its starting public offering.
The very soon spinoff Kenvue is aiming to increase $3.5 billion or more in the offering, people known with the matter told the Journal.
The newspaper stated that “the share sale would be the biggest of a quiet year for IPOs.”
Kenvue is looking to meet with future investors as early as Monday, the reports told the Journal.
When questioned about the Journal’s document, J&J spokesperson Tesia Williams stated, “Unfortunately, I do not have any information to provide” further stated.
J&J previously said it anticipates finishing the separation from Kenvue by mid-to-late 2023.
The huge consumer staples have also said it will retain majority ownership of Kenvue, with ideas to trim the rest of its stake in the year.
Kenvue’s stock trading on the New York Stock Exchange under the ticker KVUE.
J&J is revealing its plan to spin off its consumer health business in 2021. That division has created Band-Aid bandages, skin care outcomes under Neutrogena and Aveeno brands, pain relief drug Tylenol and J&J’s baby powder.
J&J still faces allegations that its talc baby powder and different talc products caused cancer.
The federal bankruptcy judge halted nearly 40,000 talc lawsuits through mid-June the previous year. That decision was part of J&J’s next attempt to settle talc shows in bankruptcy proceedings.
The temporary hold will give J&J time to win court acceptance of its $8.9 billion proposed compromise with plaintiffs in the talc cases.
Kenvue will assume talc-related liabilities that increase outside the U.S. and Canada, its IPO filing showed.
The old prestige pyramid—where Ivy League degrees and blue-chip consulting backgrounds paved the way to the CEO seat—is cracking.
Loud leaders once ruled the boardroom. Charisma was currency. Big talk drove big valuations.
But the CEOs who make history in downturns aren’t the ones with the deepest cuts
Companies invest millions in leadership development, yet many of their best executives leave within a few years. Why?
The most successful business leaders don’t just identify gaps in the market; they anticipate future needs before anyone else.
With technological advancements, shifting consumer expectations, and global interconnectedness, the role of business leaders
Maushum Basu is a visionary leader who inspires his team with a clear, compelling purpose. Unafraid to take calculated risks, he understands that growth often stems from change and innovation. His deep commitment to both Airia Brands, Inc.
When speaking with Martin Paquette, one thing is immediately apparent: he’s honest. His transparency is refreshing. While many shy away from such vulnerability, Paquette sees it as a force to reckon with. The incredible emotional intelligence speaks to years of looking within—it’s also what allows him to acknowledge his mistakes gracefully and use them as opportunities to innovate.
Marina Charriere, CEO of Star Drug Testing Services, Star Drug Testing Services (Windsor Park), and First Defence Face Masks go hand in hand. Star is a drug and alcohol testing facility, and First D F M is a face mask company.
Lejjy Gafour, CEO, CULT Food Science Corp. Lejjy is a self-taught entrepreneur and experienced company operator who made his start creating opportunities at the young age of 14, and he has been working, leading, and building businesses ever since.
Leave us a message
Subscribe
Fill the form our team will contact you
Advertise with us
Fill the form our team will contact you
